Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A-CUBE and ProtevoBio have formed a collaborative research agreement (CRA) to design and construct three biobetter therapeutic monoclonal antibodies (MAbs).
Subscribe to our email newsletter
A-CUBE, a venture capital backed company (funded by JAIC and Ben du Pont’s yet2ventures.com), uses proprietary in silico algorithms to develop various monoclonal antibodies and candidate DNA vaccines for the treatment of diseases.
ProtevoBio provides services and co-development opportunities with a focus on antibody and protein engineering for biosimilars, biobetters, innovative antibodies and Fc fusion proteins.
A-CUBE founder and president Nobu Ota said as a result of this exciting collaboration the company now has sophisticated wetlab antibody engineering skills to expand their therapeutic monoclonal antibody program.
ProtevoBio founder and CEO Jeng Her said the ability to have in silico Rational Antigen Design capability that identifies biologically functional novel peptides that can additionally gain Composition of Matter IP is very powerful.